@misc{10481/107728,
year = {2011},
month = {8},
url = {https://hdl.handle.net/10481/107728},
abstract = {Bacillus Calmette-Guerin (BCG) immunotherapy is a standard treatment for high-risk non-muscle-infiltrating bladder cancer patients. Although the outcomes are good, cancer relapse is observed in around 40% of patients. We present the comparative analysis of human leukocyte antigen (HLA) class I expression in recurrent bladder tumors in patients treated with mitomycin or BCG. HLA class I expression was analyzed by RT-Q-PCR and immunohistochemical techniques. Loss of heterozygosity (LOH) was determined by microsatellite amplification of markers in chromosome 6 and 15. More profound alterations in HLA class I expression were found in post-BCG recurrent tumors than in pre-BCG lesions, whereas mitomycin treatment did not change the HLA class I expression pattern. Post-BCG recurrent tumors also showed a higher incidence of structural defects underlying altered HLA class I expression. We hypothesize that the immunotherapy-activated immune system recognizes and eliminates tumor cells with reversible ("soft") HLA class I changes but not transformed cells with additional, irreversible ("hard") alterations. To our knowledge, this is the first clinical evidence of immunotherapy-induced immunoselection of HLA class I loss tumor variants in bladder cancer, although the study involved a small number of patients.},
organization = {Virgen de las Nieves University Hospital, Granada},
organization = {University of Granada, Spain},
publisher = {Wiley},
keywords = {Cancer},
keywords = {Immunotherapy},
keywords = {BCG},
keywords = {Bladder},
keywords = {HLA},
title = {Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells},
doi = {10.1002/ijc.25733},
author = {Carretero Coca, Rafael and Cabrera Castillo, María Teresa and Gil, Hernani and Sáenz-López, Pablo and Maleno, Isabel and Aptsiauri, Natalia and Cózar Olmo, José Manuel and Garrido Torres-Puchol, Federico},
}